Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, genetic analysis specialist Illumina (Nasdaq: ILMN ) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Illumina's business and see what CAPS investors are saying about the stock right now.
||San Diego, Calif. (1998)
||Life sciences tools and services
||CEO Jay Flatley
CFO Marc Stapley
|Return on Equity (average, past 3 years)
||$1.3 billion / $824.7 million
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 94% of the 719 members who have rated Illumina believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, slycat910, touched on the tailwinds working in Illumina's favor:
Very interesting company for a long run buy. Great prospects as a company. Genome sequencing will only become more popular over the next few years and [Illumina] is the leader in this field. As they make advances in this field driving down the price it will become more affordable to everyday people and soon be an essential part of modern health care as genome sequencing can be very useful as a preventative measure for almost all major illnesses.
If you want market-beating returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Illumina may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.